Skip to main content

Table 2 Univariate Cox proportional hazards regression analysis

From: Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma

Characteristic

DFS (n = 717)

DMFS (n = 717)

OS (n = 717)

 

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Age, (≥47 vs. < 47 years)

0.73

0.51 to 1.06

0.100

0.87

0.56 to 1.33

0.517

0.85

0.56 to 1.29

0.444

Male vs. Female

1.08

0.71 to 1.65

0.726

1.48

0.86 to 2.54

0.162

0.92

0.64 to 1.65

0.922

Histology, WHO type (III vs. II)

0.95

0.42 to 2.53

0.949

0.69

0.28 to 1.70

0.689

1.78

0.56 to 5.62

0.328

ECOG (2 vs. 0–1)

1.10

0.15 to 7.85

0.927

1.05

0.36 to 6.53

0.596

1.25

0.14 to 8.99

0.824

Clinical stage (III-IV) vs. (I-II)

3.05

1.34 to 6.94

0.008

4.43

1.40 to 14.01

0.011

2.56

1.04 to 6.31

0.041

Tumour stage (T3-4 vs. T1-2)

1.47

0.93 to 2.31

0.100

1.65

0.94 to 2.88

0.08

1.32

0.80 to 2.18

0.286

Node stage (N2-3 vs. N0-1)

1.72

1.19 to 2.48

0.004

2.19

1.40 to 3.42

0.001

1.75

1.16 to 2.66

0.008

Chemoradiotherapy (yes v no)

1.94

0.90 to 4.17

0.089

1.58

0.69 to 3.63

0.279

1.59

0.70 to 3.64

0.27

IMRT vs. 2DRT/3DCRT

0.55

0.38 to 0.80

0.002

0.66

0.42 to 1.04

0.071

0.88

0.57 to 1.34

0.537

High DNA Vs. Low DNA

2.97

2.02 to 4.36

< 0.001

3.69

2.30 to 5.91

< 0.001

3.50

2.23 to 5.50

< 0.001

CRP, mg/L (≥1.61vs. < 1.61)

1.43

0.99 to 2.06

0.055

1.83

1.18 to 2.84

0.007

1.87

1.23 to 2.85

0.003

VCA-IgA (≥1:80 vs. < 1:80)

1.39

0.91 to 2.13

0.127

1.32

0.81 to 2.16

0.267

0.95

0.64 to 1.61

0.952

EA-IgA (≥1:10 vs. < 1:10)

1.23

0.85 to 1.77

0.282

1.17

0.76 to 1.81

0.477

0.99

0.66 to 1.50

0.977

LDH, U/L (≥167 vs. < 167)

1.41

0.98 to 2.04

0.064

1.67

1.07 to 2.59

0.002

1.38

0.92 to 2.08

0.125

D-dimer, ug/L (≥0.8 vs. < 0.8)

1.88

1.28 to 2.77

0.001

2.16

1.38 to 3.36

0.001

1.98

1.29 to 3.04

0.002

WBC, 109/L (≥6.7 vs. < 6.7)

1.06

0.90 to 1.25

0.753

1.17

0.76 to 1.9

0.481

1.08

0.72 to 1.62

0.709

Neutrophil, 109/L (≥4.1 vs. < 4.1)

1.09

0.76 to 1.56

0.658

1.03

0.67 to 1.57

0.9

1.24

0.82 to 1.87

0.308

HGB, g/l (≥143.8 vs. < 143.8)

0.87

0.61 to 1.25

0.463

0.82

0.53 to 1.25

0.35

0.77

0.51 to 1.16

0.207

PLT, 109/L (≥227 vs. < 227)

1.13

0.79 to 1.62

0.511

1.08

0.71 to 1.66

0.712

1.23

0.82 to 1.84

0.33

Smoking (yes vs. no)

1.27

0.88 to 1.84

0.196

1.59

1.04 to 2.44

0.033

1.22

0.81 to 1.84

0.346

Chronic HBV Infection (yes vs. no)

1.00

0.84 to 1.18

0.953

1.02

0.84 to 1.23

0.881

0.97

0.80 to 1.18

0.969

cardiovascular disease (yes v no)

1.16

0.61 to 2.22

0.653

1.28

0.62 to 2.67

0.5

1.64

0.79 to 3.41

0.184

Diabetes mellitus (yes v no)

0.94

0.85 to 1.05

0.286

0.97

0.87 to 1.08

0.592

0.94

0.84 to1.05

0.248

family history of NPC (yes v no)

1.14

0.61 to 2.11

0.686

1.13

0.55 to 2.35

0.735

1.14

0.92 to 1.41

0.241

  1. Abbreviations: ECOG  Eastern Cooperative Oncology Group, 2DRT  two-dimensional radiotherapy, 3DCRT  three-dimensional conformal radiotherapy, IMRT  intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of <4000 copies/ml, High DNA denotes a high EBV DNA level of ≥4000 copies/ml, VCA  viral capsid antigen. IgA  immunoglobulin A, EA  early antigen, LDH  Serum Lactate Dehydrogenase Levels, CRP  high-sensitivity C-reactive protein, WBC  White blood cell, HGB  haemoglobin, PLT  platelet, NPC  nasopharyngeal carcinoma. DFS  disease-free survival, DMFS  metastasis-free survival, OS  overall survival.